A new clinical practice guideline for benzodiazepine (BZD) tapering has been published by a coalition of representatives from 10 professional medical societies, with additional input from a panel of individuals with lived experience with BZD discontinuation. The guideline provides evidence-based, consensus-derived recommendations for safely discontinuing BZDs when the risks outweigh the benefits. It emphasizes gradual tapering under clinical supervision, offers specific recommendations for special populations, and addresses the challenges and complexities of BZD discontinuation in diverse clinical circumstances.